About Ikerian AG and RetinAI Inc. U.S. Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. (‘Ikerian’, ‘RetinAI’ and, together, ‘the company’), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI’s international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. A commercial stage company with growing sales from RetinAI Discovery®, RetinAI has established collaborations and partnerships with leading ophthalmology clinical networks and pharmaceutical companies.
Powered Research
Powered Research is a leading preclinical CRO specializing in non-GLP models. Our commitment is to provide cutting-edge solutions in ophthalmology and oncology research, tailored to meet the unique needs of life science R&D companies. Our staff has extensive expertise in the design and development of non-GLP preclinical data packages, including tolerability and pharmacology models, drug distribution studies, and custom experimental designs. We strive to design the right studies for the product to support our clients’ development strategies. Powered Research is well known for rapid study turnaround, and our scientific experts allow for timely study scheduling and execution. A collection of internal protocols for specific models, and we develop custom models based on client specifications and needs.
Optos
Optos ultra-widefield imaging takes less than ½ second to improve practice flow, uncover critical information and can help prevent vision loss. It is the ONLY 200° single capture retinal image.
OcuSciences, Inc
OcuSciences, Inc., is a commercial-stage biotechnology company developing next-generation retinal imaging solutions for ocular health. The company’s proprietary technologies aim to expand how clinicians and researchers assess the eye, delivering novel insights to support care and innovation in new treatments.